Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Capital Expenditures (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Capital Expenditures over the past 3 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $3.1 million for Q4 2025, up 103433.33% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 2707.5% YoY), and the annual figure for FY2025 was $3.4 million, up 2707.5%.
  • Capital Expenditures for Q4 2025 was $3.1 million at Tonix Pharmaceuticals Holding, up from -$263000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TNXP hit a ceiling of $6.3 million in Q3 2023 and a floor of -$263000.0 in Q3 2025.
  • Median Capital Expenditures over the past 3 years was $235500.0 (2023), compared with a mean of $948666.7.
  • Peak annual rise in Capital Expenditures hit 103433.33% in 2025, while the deepest fall reached 2490.91% in 2025.
  • Tonix Pharmaceuticals Holding's Capital Expenditures stood at $438000.0 in 2023, then tumbled by 99.32% to $3000.0 in 2024, then surged by 103433.33% to $3.1 million in 2025.
  • The last three reported values for Capital Expenditures were $3.1 million (Q4 2025), -$263000.0 (Q3 2025), and $520000.0 (Q2 2025) per Business Quant data.